Afelimomab for sepsis - horizon scanning review

Citation

Authors' objectives
To summarise the available evidence on afelimomab for sepsis.

Authors' conclusions
- Clinical impact: The clinical impact associated with the introduction of afelimomab initially appears small and needs further assessment when trial results are fully published. However afelimomab is a new treatment for a patient group that has a very high mortality (50-80%) and any benefit may be clinically significant. - Service impact: It is likely that there will be some service impact associated with the introduction of afelimomab as intensive care staff will need to consider treatment and target treatment to those with high IL-6 levels. - Additional factors: There are unlikely to be any significant additional factors associated with the introduction of afelimomab, although patients and their carers will probably welcome this therapeutic option. - Financial and overall NHS impact: Due to the lack of cost data and detailed estimates of patient group, it is difficult to determine the financial impact of introducing afelimomab for severe sepsis and septic shock at this time. However the numbers of patients currently using costly health services, and eligible for consideration of therapy is significant.

Timeliness warning
Available on request from NHSC.

Final publication URL
http://www.hsric.nihr.ac.uk/search

Indexing Status
Subject indexing assigned by CRD

MeSH
Antibodies, Monoclonal /therapeutic uses; Sepsis /drug therapy; Shock, Septic /drug therapy

Language Published
English

Country of organisation
England

English summary
An English language summary is available.

Address for correspondence
Department of Public Health & Epidemiology The University of Birmingham Edgbaston, Birmingham B15 2TT United Kingdom Tel: +44 121 414 7831; Fax: +44 121 414 2269 Email: c.packer@bham.ac.uk